This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for BeneFIX® (nonacog alfa) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

Dosing that’s as individual as your patients1–3

Flexible dosing

No two days are the same. No two patients are the same.
BeneFIX offers frequent, flexible dosing so your patients are covered for everyday life1,4,5

Patients may vary in their response to factor IX, demonstrating different half-lives and recoveries1

Shorter dose intervals or higher doses may be necessary to deliver adequate coverage based on patient’s bleeding phenotype, levels of physical activity, and preference regarding convenience and adherence1–3

BeneFIX offers frequent, flexible dosing1

BeneFIX comes in a range of vial sizes, so you can individualise factor IX coverage for your patients1

BeneFIX can be given as on-demand treatment or as prophylaxis1

BeneFIX offers patients storage flexibility through room temperature storage (<30ºC)1

So your patients are covered for everyday life1,4,5

​​​​​​​Dosing Optimisation with BeneFIX

​​​​​​​Achieving Medicines Optimisation with BeneFIX

What is medicines optimisation and what are the benefits?

Medicines optimisation is a patient focused approach which aims to improve the outcome for patient treatment, by making sure that medicines are being used safely and in the most effective way possible.6,7  It also allows the NHS to make sure that medicines being used are both clinically and cost effective.6

BeneFIX is competitively priced and delivers value both financially and for patients, allowing for optimisation of NHS resources.

The quality of life for patients with haemophilia can be greatly improved through reduced bleeds and by aiming to keep baseline factor level above 5% which reduces the chance of spontaneous bleeding.8

How can BeneFIX allow for improved medicines optimisation?

  • Cost effective treatment for patients
  • Range of vial sizes – which allows for individualised dosing1
  • Storage flexibility – can be stored at room temperature (<30C)1
  • Predictable pharmacokinetic profile


How medicines optimisation with BeneFIX can improve a patient's lifestyle? 2,9

  • Aims to increase coverage for day to day activities
  • Aims to prevent spontaneous breakthrough bleeding
  • Aims to prevent subclinical bleeding and ensuing joint damage

Explore more

Find out about adminsitration & reconstitution of BeneFIX

Click here

Find out about dosing of BeneFIX for on-demand treatment & prophylaxis

Click here

References
  1. BeneFIX (nonacog alfa) Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/6157/smpc.
  2. Shapiro AD et al. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005;11:571–582.
  3. Berntorp E and Andersson NG. Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products. Semin Thromb Hemost 2016;42:518–525.
  4. Mahdi AJ et al. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol. 2015;169:768–776.
  5. Collins PW, et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17:2–10.
  6. Medicines Optimisation. https://www.england.nhs.uk/medicines-2/medicines-optimisation/ Accessed September 2020.
  7. Medicines Optimisation: the safe and effective use of medicines to enable the best possible outcomes. https://www.nice.org.uk/guidance/ng5 Accessed September 2020
  8. Shapiro A et al. Association of Bleeding Tendency With Time Under Target FIX Activity Levels In Severe Haemophilia B Patients Treated With Recombinant Factor IX Fc Fusion Protein. Blood. 2013:122(21): 2349.
  9. Jiménez-Yuste, V. et al. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfusion. 2014:12(3): 314-319
PP-BEN-GBR-0393. March 2021

Contact Pfizer

Speak to a member of the Pfizer haemophilia team.

Click here

Find out about BeneFIX efficacy 

Click here

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No